Sorry no one answered your question.
The short answer is no, it is not a must have for duplication.
What it is though is a must have for affordable duplication. Other methods of duplication result in a finite amount of cells from a single donation/harvest meaning the cost of manufacturing is relatively high resulting in high cost of treatment. CYP can duplicate basically an infinite amount from a single donation/harvest which significantly lowers production and treatment costs. CYP will eventually bring affordable stem cell based therapies to the masses. When is the big question as we are dragging our feet a bit.
All the above is before we even start to look at efficacy of one cell compared to another (ours are very good).
-
- There are more pages in this discussion • 1,711 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
-0.005(3.03%) |
Mkt cap ! $36.15M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 16.5¢ | 16.0¢ | $73.23K | 457.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 31250 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 27550 | 2 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |